Prospective sero surveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India
Authors:
- Swathi Krishna NjarekkattuvalappilSNSwathi Krishna Njarekkattuvalappil
- Ramesh BhaskaranRBRamesh Bhaskaran
- Sree Raj VSVSree Raj V
- Ponnu JosePJPonnu Jose
- Aboobacker Mohammed RafiARAboobacker Mohammed Rafi
- Joe ThomasJTJoe Thomas
- Susheela J InnahSISusheela J Innah
- Lucy RaphaelLRLucy Raphael
- Unnikrishnan U GUGUnnikrishnan U G
- Priyanka RajmohanPRPriyanka Rajmohan
- Chithra ValsanCVChithra Valsan
- Praveenlal KuttichiraPKPraveenlal Kuttichira
Preprint
Abstract
Background: India started Covid-19 vaccination from January 16, 2021 after the approval of two candidate vaccines namely Covishield ™ and Covaxin ™. We report antibody responses among healthcare workers following two doses of Covishield ™ vaccination in a tertiary care setting. Methods: This prospective serosurveillance study was done among healthcare workers of Jubilee Mission Medical College, vaccinated during January- March 2021. Blood samples were drawn from 170 participants after their 1 st dose and from 156 participants after their 2 nd dose of Covishield ™ to measure the specific Ig G antibodies against the recombinant S1 subunit of the S protein of SARS-CoV-2. Results: The median level of anti SARS CoV-2 Ig G antibody 28 days after the first dose vaccination is 3.64 S/C (IQR=5.91) and 11.6 S/C (IQR= 5.97) after 14 days of second dose vaccination. Protective levels of anti SARS CoV-2 Ig G antibodies is developed by 25 participants (14.7%) after 28 days of first dose of vaccination and by 109 participants (69.9%) after 14 days of second dose. 18-44 years age group (p=0.027) and absence of comorbidities (p=0.079) are associated with protective IgG levels. Conclusions: Rise in specific Ig G is observed after vaccination. Higher antibody response is observed with younger age group and absence of comorbidities, though statistically not significant. The influence of BMI is also not significant.Keywords
All Related Versions
- Published version: Sechenov Medical Journal, 13 (1), 14.
This publication has 16 references indexed in Scilit:
- Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccinationmedRxiv, 2021
- Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infectionMed, 2021
- Persistence of IgG response to SARS-CoV-2The Lancet Infectious Diseases, 2021
- Serosurveillance of SARS CoV 2 among the healthcare workers of a tertiary care teaching institution in Central Kerala during the post lockdown phasemedRxiv, 2021
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialNature Medicine, 2020
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activityEBioMedicine, 2020
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidatesThe Lancet, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Influence of immune aging on vaccine responsesJournal of Allergy and Clinical Immunology, 2020